Skip to main content

Table 3 Clinical, laboratory, and radiologic features at first examination

From: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

 COVID-19 patients, N pts/N evaluable (%)RNA-positive subgroup, N pts/N evaluable (%)
Clinical examination
 Fever (≥ 38.0 °C)27/59 (46%)21/41 (51%)
 Cough22/59 (37%)18/41 (44%)
 Dyspnea17/59 (29%)10/41 (24%)
 Decreased saturation (< 96%)7/59 (12%)5/41 (12%)
 GI disorders6/59 (10%)5/41 (12%)
 Headache3/59 (5%)3/41 (7%)
 Anosmia/dysgeusia5/59 (8%)4/41 (10%)
 Possible nosocomial infection9/59 (15%)8/41 (20%)
Laboratory parameters
 Neutrophil count: mean (IQR) (G/L)4.0 (2.0–5.1), N = 494.3 (2.0–5.0), N = 31
 Lymphocyte count: mean (IQR) (G/L)1.5 (0.8–1.9), N = 491.5 (1.3–3.9), N = 31
 LDH > ULN11/12 (92%)4/4 (100%)
CT scan available for central review
 Extent of lesions (% of lung volume)
  No lesion2/28 (7%)2/14 (14%)
  < 10%11/28 (39%)2/14 (14%)
  10–25%12/28 (42%)8/14 (57%)
  26–50%2/28 (7%)1/14 (7%)
  51–75%1/28 (4%)1/14 (7%)
  > 75%0/28 (0%)0/14 (0%)
 Predominant type of lesion
  No lesion2/28 (7%)2/14 (14%)
  Ground-glass opacities14/28 (50%)7/14 (50%)
  Crazy paving4/28 (14%)1/14 (7%)
  Focal consolidation7/28 (25%)3/14 (22%)
  Linear consolidation1/28 (0%)1/14 (7%)
 Loco-regional radiation therapy
  No radiation therapy9/28 (32%)8/14 (57%)
  No sequela (0%)8/28 (29%)4/14 (29%)
  Sequela extent: 1–10% of lung volume9/28 (32%)2/14 (14%)
  Sequela extent: 11–25% of lung volume2/28 (7%)0/14 (0%)
  Sequela extent: > 25% of lung volume0/28 (0%)0/14 (0%)
  1. Nosocomial infection refers to a new infection diagnosed > 2 days after admission to hospital. GI gastrointestinal, ULN upper limit of normal